SB 525

Drug Profile

SB 525

Alternative Names: AAV cDNA gene therapy - Sangamo Therapeutics; AAV cDNA hF8 gene therapy; AAV cDNA human Factor 8 gene therapy; AAV Factor 8 cDNA gene therapy; AAV Factor 8 cDNA in vivo gene therapy; Recombinant AAV2/6 Human Factor 8 Gene Therapy - Sangamo Therapeutics; SB-525; SB-525 cDNA gene therapy

Latest Information Update: 09 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sangamo BioSciences
  • Developer Sangamo Therapeutics
  • Class Antihaemorrhagics; Gene therapies
  • Mechanism of Action Factor VIII stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Haemophilia A

Most Recent Events

  • 07 Jun 2017 SB 525 receives Orphan Medicinal Product status for Haemophilia A in European Union
  • 02 Jun 2017 Phase-I/II clinical trials in Haemophilia A in USA (IV) (NCT03061201)
  • 16 May 2017 SB 525 receives Fast Track designation for Haemophilia A [IV] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top